L&G Pharma Breakthrough UCITS ETF

ISIN IE00BF0H7608 Rating ★☆☆☆☆

Replication
physical

Earnings
accumulating

Asset class
Equity

Sector
Biotechnology

TER
0.49 %

TD
0.70 %

Currency
USD

Fund size
29 Mio EUR

Perf. 2020
27.10 %

"L&G Pharma Breakthrough UCITS ETF" is an exchange-traded investment fund (ETF). It refers to the Solactive Biotechnology Breakthrough Value Index. This index reflects the development of stocks . The ETF replicates its index using full physical replication, so it contains all the securities of its reference index. The ETF's earnings (dividends) are automatically reinvested (accumulated). The fund company L&G ETF claims a total expense ratio (TER) of 0.49% per year. The yearly average divergence from the index performance (Tracking Difference) since 2019 was 0.70% per year. Therefore, the ETF was more expensive than the TER suggests.

Tracking Differences

Performance

Fund size

ETFs on the Solactive Biotechnology Breakthrough Value Index

Settings
appearance

switch dark mode

data usage